Thus, alterations in acrolein metabolism and detoxification due to GSTP1 gene polymorphism may potentially contribute to the difficulty in treating and maintaining desired HbA1c values among T2D patients. The gene discussed is GSTP1; the disease is type 2 diabetes mellitus.